New cardiovascular drug by AstraZeneca

AstraZeneca has demonstrated interim results in a clinical trial of myeloperoxidase inhibitor in patients with heart failure with preserved ejection fraction.

A phase 2 of the study evaluated the safety, efficacy, and tolerability of AZD4831 in patients with heart failure with preserved ejection fraction. In the middle of the study, it was concluded that AZD4831 group showed a decrease in myeloperoxidase activity by 69% compared with baseline to 30 days.

Also, patients taking AZD4831 experienced increased endurance and improved well-being. Molecular studies have found that proteomic abnormalities, associated with increased morbidity and mortality in patients with heart failure and preserved ejection fraction, were practically reversed. This is associated with AZD4831 therapy, accordingly.

Source: PharmaPhorum